Cargando…
Long-term safety of bilateral targeted lung denervation in patients with COPD
BACKGROUND: Targeted lung denervation (TLD) is a novel bronchoscopic therapy for COPD which ablates parasympathetic pulmonary nerves running along the outside of the two main bronchi with the intent of inducing permanent bronchodilation. The goal of this study was to evaluate the feasibility and lon...
Autores principales: | Valipour, Arschang, Asadi, Sherwin, Pison, Christophe, Jondot, Marie, Kessler, Romain, Benneddif, Khaled, Deslee, Gaetan, Verdier, Margaux, Slebos, Dirk-Jan, Mayse, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052931/ https://www.ncbi.nlm.nih.gov/pubmed/30038492 http://dx.doi.org/10.2147/COPD.S158748 |
Ejemplares similares
-
Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes
por: Christophe, Pison, et al.
Publicado: (2021) -
Correction to: Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes
por: Pison, Christophe, et al.
Publicado: (2021) -
Targeted lung denervation for moderate to severe COPD: a pilot study
por: Slebos, Dirk-Jan, et al.
Publicado: (2015) -
Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2
por: Valipour, Arschang, et al.
Publicado: (2020) -
Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira® lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3)
por: Slebos, Dirk-Jan, et al.
Publicado: (2020)